Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MYTDfZRwfG:6aXPpeJkh[XO|YYm= NHXEZ244OiCq NHK4c|VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1zMjDuUS=> M2TkW|E6PjV2NEC4
RS4-11 cells NVWxcFVLTnWwY4Tpc44h[XO|YYm= NX;FNlVFOiCq NUHRTINCUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDSV|QuOTFiY3XscJMh[W[2ZYKgNkBpenNiYomg[Yxm[3S{b3Po[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwQVE{KG6P MVixPVY2PDRyOB?=
CGTH-W-1 cell NXP0dGk3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlX4TY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=> M2W0OHNCVkeHUh?=
SW982 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHryZVdKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvPThizszN NUjV[4JOW0GQR1XS
human EoL-1-cell cell M{jvRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> MlrDV2FPT0WU
MOLM-13 cells NYfmTllNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjHXolCPzJiaB?= NHLyUJJKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjleIVzd3q7Z3;1d{BufXSjboSgbY4hcHWvYX6gUW9NVS1zMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUC9NE4xPTVizszN NEfUNYszPjB6MUCyNy=>
KASUMI-1 cell M3ruW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWT5ZohoUW6qaXLpeIlwdiCxZjDoeY1idiCNQWPVUWkuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[wNVYh|ryP MYHTRW5ITVJ?
NCI-H1755 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\UWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkK3N{DPxE1? NXrCTVVtW0GQR1XS
human MES-SA cell M1XnOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7JOog3UW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? MoD4V2FPT0WU
human HCC1395 cell NX;4Uo85T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfLTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDR{ODFOwG0> NFLxNo1USU6JRWK=
human D-336MG cell Ml7KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3fiPGlvcGmkaYTpc44hd2ZiaIXtZY4hTC1|M{\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5NUSg{txO NIfmc|NUSU6JRWK=
CHP-212 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPh[FhqUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe3N{DPxE1? NYqxUI9mW0GQR1XS
human KM12 cell NYrwNohWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\yOm1JUW6qaXLpeIlwdiCxZjDoeY1idiCNTUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTJ5NTFOwG0> NY[ycIY6W0GQR1XS
A204 cell NIXRSoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGwNFUzKM7:TR?= MmjPV2FPT0WU
CAL-51 cell NWrqUlMyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mle2TY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=> MoPaV2FPT0WU
human A431 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnyTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVIyPiEQvF2= M2fI[3NCVkeHUh?=
NCI-H650 cell MnXaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTdyODFOwG0> MV3TRW5ITVJ?
A427 cell M2\KWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFH5NlZKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=> MoDEV2FPT0WU
human 769-P cell M1W2T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M325bGlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=> M1WwZ3NCVkeHUh?=
SW1710 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXjJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM{OTZizszN MkHhV2FPT0WU
human H4 cell M1nPRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEDRPIdKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|k3OyEQvF2= NVXyfFFLW0GQR1XS
HT-1080 cell NV3hR2JwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\NV45bUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NkDPxE1? M3zjSXNCVkeHUh?=
human PANC-03-27 cell Mni5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNvMEOtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4MEKg{txO MWDTRW5ITVJ?
A375 cells M3LFcGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1S2OlczKGh? NXjvcI1yXG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUC9NE4yQCEQvF2= NF;mZWYyQTZ3NESwPC=>
human HOP-62 cell MWTGeY5kfGmxbjDhd5NigQ>? NFXBNIRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO MUnTRW5ITVJ?
human U031 cell M{m0O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLHU3FKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6Pjl6IN88US=> MlrMV2FPT0WU
mouse BAF3 cells MoHVVJJwdGmoZYLheIlwdiCjc4PhfS=> MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1? MUmyNVk{PjV2Mh?=
human G-402 cell M{XiXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\TTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlAzPTNizszN NVPrZ4tnW0GQR1XS
human G-361 cell NYrQfWt[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3v3WmlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxQDV|IN88US=> NHzT[ppUSU6JRWK=
NCI-H810 cell M1;iWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnY[4lvUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkGwNlch|ryP M2T1[nNCVkeHUh?=
NCI-H2030 cell Mnm1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MonUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|MEC2JO69VQ>? NULhdmZvW0GQR1XS
human HCT-116 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PTZ6IN88US=> MUHTRW5ITVJ?
human SNU-423 cell M3f3V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrrTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0> M{mye3NCVkeHUh?=
human SCC-4 cell NHLCUG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mne1TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlM6PjdizszN MmHIV2FPT0WU
human SW48 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfVOpFQUW6qaXLpeIlwdiCxZjDoeY1idiCVV{S4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPjZ6IN88US=> NXrQb3VUW0GQR1XS
human SF295 cell M2fRWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHS4UHJKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzJ3NzFOwG0> NHjue|NUSU6JRWK=
MDA-MB-231 cell Mo\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fIVmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkixNFEh|ryP Mmq3V2FPT0WU
A172 cell NHTqc3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MofPTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPVE2KM7:TR?= NIe0dVdUSU6JRWK=
human BCPAP cell M2LaUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIjmS3hKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> MnXOV2FPT0WU
human COLO-792 cell MnzGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGq2WYdKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{OUm3NkDPxE1? NEK0[3dUSU6JRWK=
human DU-145 cell NWLEV4pJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmDlTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMyQDh7IN88US=> MU\TRW5ITVJ?
NCI-H2122 cell MkjyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jBOWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkK4OUDPxE1? MV;TRW5ITVJ?
human SK-UT-1 cell NXLsWHFsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> NXflZ41[W0GQR1XS
LXF-289 cell NF3qdYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX:2[GRRUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkm2OUDPxE1? NH\XRmNUSU6JRWK=
human NCI-H1792 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rPbmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{C5OkDPxE1? NIfCZVZUSU6JRWK=
MCF7 cell NGHaU|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33VUmlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|MzPzRizszN MkLVV2FPT0WU
HCT-15 cell NES4[45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;0eGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR|MjFOwG0> MV;TRW5ITVJ?
human NCI-H358 cell NF7WNVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> M3mxZnNCVkeHUh?=
human HLE cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3HPPGlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zN|c2OiEQvF2= MV7TRW5ITVJ?
human SW1088 cell NUfoV3E4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWDwfYRuUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|N{m3JO69VQ>? NW\GNVkxW0GQR1XS
human K5 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoTCTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP MUXTRW5ITVJ?
human SR cell MmrUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfHTY5pcWKrdHnvckBw\iCqdX3hckBUWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[1O|Eh|ryP NGjDOHRUSU6JRWK=
human Calu-3 cell NHvxW4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y5OjVizszN M1qxfXNCVkeHUh?=
human SK-MEL-30 cell MnzpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2nNPGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OUmxN{DPxE1? NHyxTnJUSU6JRWK=
human SW780 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYThN29xUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDFzNEKg{txO NXnqbGZ1W0GQR1XS
NCI-H1563 cell M4nGcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPvd3Z4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?= M4rXbnNCVkeHUh?=
human MKN45 cell NXTHeHhxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmLRTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFE6OzFizszN NYDDPGdDW0GQR1XS
MDA-MB-157 cell NXLRTWtPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPBTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkCxOUDPxE1? M17xXHNCVkeHUh?=
human NCI-H522 cell NHjHUnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVnISXN3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? NFz6bnNUSU6JRWK=
human A2780 cell NXW4[5I6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELNfGpKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzVyMzFOwG0> NHLpOGhUSU6JRWK=
human A498 cell NH\PT5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzlTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|Y6OyEQvF2= M{HOUnNCVkeHUh?=
human BxPC-3 cell NFnUZXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJGJ5WENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFk{PjZizszN NE[0e2RUSU6JRWK=
human A2058 cell M4HLR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYS4T2llUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ6NESg{txO M4H5XnNCVkeHUh?=
human PC-14 cell NHT0XpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7FNGMyUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO NHHUVmRUSU6JRWK=
human KG-1 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1XnXmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN M17IeHNCVkeHUh?=
human A375 cell NXHmS|d2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?= NXPa[FVqW0GQR1XS
human SW1783 cell MnnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEXEfZFKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzN|NzFOwG0> MVfTRW5ITVJ?
human MKN1 cell M2XrUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITHUohKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> MlftV2FPT0WU
NCI-H1650 cell NGPpUldIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2qyZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?= MWjTRW5ITVJ?
human HT-1376 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4XyWGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO M{LWW3NCVkeHUh?=
SW872 cell MoPZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7EPJZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> MVfTRW5ITVJ?
human RT-112 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVH5ZpBJUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl5NEizJO69VQ>? NVnFOW1tW0GQR1XS
human HT-29 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvaTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc6QTZizszN M3jjZnNCVkeHUh?=
human U-266 cell MmDxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFMxOiEQvF2= Ml23V2FPT0WU
human HEL cell M1LVcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUi1NVch|ryP M3nNbnNCVkeHUh?=
human KU812 cell M4PWTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xNVE3PCEQvF2= Mn7LV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 100 mg/mL warmed (175.24 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 300+ddH2O
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID